daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine, glimidac range, diabetix products, glimidac-1, glimidac 2
daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine, glimidac range, diabetix products, glimidac-1, glimidac 2, glimidac pm forte, glimidac pm2 forte, glimidac pm-1 forte
daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine, glimidac range, diabetix products, glimidac-1, glimidac 2
daksh diabetic and cardiac, dalsh cardiac, daksh pharmaceuticals , daksh pharma panchkula, cardiac pcd franchise, daksh panchkula, cardiac medicine, heart medicine, glimidac range, diabetix products, glimidac-1, glimidac 2, glimidac pm forte, glimidac pm2 forte, glimidac pm-1 forte

GLIMIDAC -PM FORTE

TAB GLIMIDAC -PM 1 FORTE (Glimepiride 1mg + Pioglitazone 15 mg
+ Metformin  500 mg (SR))		 BLISTER 10 X 10
TAB GLIMIDAC PM 2 FORTE (Glimepiride  2 mg + Pioglitazone 15 mg
+ Metformin HCL 500 mg (SR))		 BLISTER 10 X 10
TAB GLIMIDAC PM 3 FORTE (Glimepiride 3 mg + Pioglitazone 15 mg
+ Metformin HCL 500 mg (SR))		 BLISTER 10 X 10
Category: Tag:
Send Enquiry

Introduction:

GLIMIDAC-PM FORTE is a comprehensive triple-drug oral antidiabetic therapy combining Glimepiride, Metformin SR, and Pioglitazone. This formulation is designed for patients with Type 2 Diabetes Mellitus (T2DM) who are not adequately controlled on dual therapy. It targets multiple pathophysiological defects: insulin resistance, impaired insulin secretion, and increased hepatic glucose production.

Each variant is available in blister packs (10 x 10 tablets) for optimal convenience and patient compliance.

Product Variants & Composition:

  1. GLIMIDAC-PM 1 FORTE

    • Composition: Glimepiride 1 mg + Pioglitazone 15 mg + Metformin 500 mg (SR)

    • Packaging: Blister | 10 x 10 Tablets

  2. GLIMIDAC-PM 2 FORTE

    • Composition: Glimepiride 2 mg + Pioglitazone 15 mg + Metformin HCl 500 mg (SR)

    • Packaging: Blister | 10 x 10 Tablets

  3. GLIMIDAC-PM 3 FORTE

    • Composition: Glimepiride 3 mg + Pioglitazone 15 mg + Metformin HCl 500 mg (SR)

    • Packaging: Blister | 10 x 10 Tablets

Key Benefits:

  • Triple Mechanism of Action:

    • Glimepiride: Stimulates insulin secretion from pancreatic β-cells.

    • Metformin: Reduces hepatic glucose production and improves peripheral glucose uptake.

    • Pioglitazone: Enhances insulin sensitivity in muscle and adipose tissues.

  • Effective for long-standing or poorly controlled diabetes.

  • Reduces HbA1c significantly over monotherapy or dual therapy.

  • Decreases progression of diabetes complications.

  • Encourages better patient adherence with once-daily dosing.

Indications:

  • Type 2 Diabetes Mellitus inadequately controlled with diet, exercise, and dual oral therapy.

  • Patients with obesity, insulin resistance, and elevated fasting glucose.

  • Ideal alternative before initiating insulin therapy.

Dosage & Administration:

  • Recommended dose: One tablet once daily with the largest meal of the day.

  • Dosage should be tailored based on the patient’s glycemic profile and clinical judgment.

  • Regular monitoring of blood glucose, HbA1c, renal and hepatic parameters is advised.

Precautions & Warnings:

  • Not to be used in Type 1 Diabetes or Diabetic Ketoacidosis.

  • Use with caution in patients with heart failure, hepatic dysfunction, or osteoporosis.

  • Discontinue use if signs of hepatic impairment, fluid retention, or unexplained weight gain appear.

  • Not recommended during pregnancy or lactation.

Possible Side Effects:

  • Hypoglycemia, especially if meals are skipped or delayed.

  • Weight gain or peripheral edema (due to Pioglitazone).

  • Gastrointestinal disturbances (nausea, bloating, diarrhea – from Metformin).

  • Rare: Lactic acidosis, liver enzyme elevation, or fracture risk with long-term use.

Conclusion:

The GLIMIDAC-PM FORTE range offers a powerful triple oral therapy option for patients with T2DM not adequately controlled by dual agents. Its once-daily regimen improves compliance and addresses insulin resistance, β-cell dysfunction, and hepatic glucose output simultaneously.

Choose GLIMIDAC-PM FORTE for a holistic, proven approach to advanced glycemic control.

Note : Always Consult a physician before taking any medication, and do not rely solely on this information for medical advice.

For more such product information and similar product category Diabetic

You can also contact us  https://diabetes-cardiac.com/contact-us/

Related products